ReviewRespiratory research2025
Respiratory microphysiological system in respiratory research: recent advances and future prospects.
Review in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Preparation and Infection of Bovine Precision-Cut Lung Slices (b-PCLS) as an Ex Vivo Model for Respiratory Pathogens.Current protocols · 2026Article
- Robust generation of distal respiratory airway organoids by an engineered cuboid chip.Journal of nanobiotechnology · 2026Article
- Application and prospects of lung organ-on-a-chip in the development of new drugs.Biomedical engineering online · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Respiratory diseases encompass a broad range of conditions that affect the airways, alveolus, and other structures involved in breathing. With respiratory viruses emerging and spreading rapidly, and factors like air pollution, smoking, occupational hazards, and genetics as major risk contributors, respiratory diseases have emerged as a primary cause of illness and mortality around the globe. The development of in vitro respiratory microphysiological systems (MPS), like lung organoids and lung-on-a-chip models, is essential for preventing and treating these diseases effectively. In this review, we introduce the generation of lung organoids from different cellular sources and their applications in modeling lung development, disease models, and drug screening. Then, we discuss the establishment of various types of lung-on-a-chip models and their applications in disease modeling and drug screening. Finally, we outline the challenges confronting respiratory MPS and provide an outlook on their future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.